Inhibition of HSP90 molecular chaperones: moving into the clinic.
about
Identification of sequences common to more than one therapeutic target to treat complex diseases: simulating the high variance in sequence interactivity evolved to modulate robust phenotypesGanetespib: research and clinical developmentTargeting Hsp90 in urothelial carcinomaSynergistic Activity of Deguelin and Fludarabine in Cells from Chronic Lymphocytic Leukemia Patients and in the New Zealand Black Murine ModelExploiting Protein Conformational Change to Optimize Adenosine-Derived Inhibitors of HSP70.Anti-Hsp90 therapy in autoimmune and inflammatory diseases: a review of preclinical studiesNovel therapeutic strategies for multiple myelomaOvine pulmonary adenocarcinoma: a large animal model for human lung cancerHuman Genetic Relevance and Potent Antitumor Activity of Heat Shock Protein 90 Inhibition in Canine Lung Adenocarcinoma Cell LinesGambogic acid identifies an isoform-specific druggable pocket in the middle domain of Hsp90βALK-rearrangements and testing methods in non-small cell lung cancer: a reviewCorrelation between PDZK1, Cdc37, Akt and breast cancer malignancy: the role of PDZK1 in cell growth through Akt stabilization by increasing and interacting with Cdc37Protein chaperones: a composition of matter review (2008 - 2013).Synergetic cytotoxic activity toward breast cancer cells enhanced by the combination of Antp-TPR hybrid peptide targeting Hsp90 and Hsp70-targeted peptide.A selenosemicarbazone complex with copper efficiently down-regulates the 90-kDa heat shock protein HSP90AA1 and its client proteins in cancer cells.Heat shock protein 90 in Alzheimer's diseaseMisfolded proteins: from little villains to little helpers in the fight against cancer.Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma.Combined pharmacological induction of Hsp70 suppresses prion protein neurotoxicity in Drosophila.The combination of Hsp90 inhibitor 17AAG and heavy-ion irradiation provides effective tumor control in human lung cancer cells.Molecular characterization and targeted therapeutic approaches in breast cancerStability of the human Hsp90-p50Cdc37 chaperone complex against nucleotides and Hsp90 inhibitors, and the influence of phosphorylation by casein kinase 2Clusterin facilitates metastasis by EIF3I/Akt/MMP13 signaling in hepatocellular carcinoma.Proteomics in cancer biomarkers discovery: challenges and applications.Geldanamycin Enhances Retrograde Transport of Shiga Toxin in HEp-2 Cells.Selection and Characterization of Single Chain Antibody Fragments Specific for Hsp90 as a Potential Cancer Targeting Molecule.Molecular Chaperones of Leishmania: Central Players in Many Stress-Related and -Unrelated Physiological Processes.Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells.The Chemical Biology of Molecular Chaperones--Implications for Modulation of ProteostasisDifferential expression of heat shock protein 90 isoforms in small cell lung cancerThe HSP90 inhibitor 17-PAG effectively inhibits the proliferation and migration of androgen-independent prostate cancer cellsFirst Structural View of a Peptide Interacting with the Nucleotide Binding Domain of Heat Shock Protein 90CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.Potential C-terminal-domain inhibitors of heat shock protein 90 derived from a C-terminal peptide helix.Ganetespib radiosensitization for liver cancer therapyHeat Shock Protein (HSP) Drug Discovery and Development: Targeting Heat Shock Proteins in Disease.Effects of treatment with an Hsp90 inhibitor in tumors based on 15 phase II clinical trials.In Vivo Conformational Dynamics of Hsp90 and Its Interactors.TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.Sulphoxythiocarbamates modify cysteine residues in HSP90 causing degradation of client proteins and inhibition of cancer cell proliferation.
P2860
Q21146715-53A63C7C-9116-44D2-817D-188F7D1E43ABQ26798645-199B1C33-37EE-49A7-985F-B2134610840CQ27023406-98C0D1C5-7B22-4CCB-9B6D-FDF7E8C8C7D2Q27312452-39D63645-EF49-42FB-A1F2-B5582B2D2850Q27704725-9104CEDC-AC75-4140-ADA6-A1C119201115Q28076199-2805106C-49C4-4ABD-AAEA-035F84780C37Q28081590-96052D47-01EF-4798-8E94-DEA79D7AA896Q28088774-87BD91CF-EB7E-4EE5-8DE1-99D7C31D26CFQ28550872-D84BA3E4-1B62-407F-860C-D396260C6CEEQ28829208-4DF07FE4-745F-430C-AA4F-12E567AC42AFQ33776835-6A302D8E-46CA-46A6-AC77-5082CEC72088Q33934600-9F915284-EA1B-402D-B9BB-07FC82A2B447Q34013266-0D3322C4-2A21-4707-8C72-2D487BACAB34Q34129993-E798E377-C329-43EF-AE08-9DA5004149FAQ34208541-45E21F11-8B38-47F0-8CE6-92D484C5FE96Q34413279-7E3BB769-2157-44BE-B92E-D0459CC8B4B4Q34466592-4E151672-E986-4A0D-AC06-087A9BF68A17Q35054403-197AF3DC-78DA-433D-BE06-B9BEB5AB143FQ35093650-360AE485-27A9-44EE-8DA3-7074269383E1Q35236805-F3E5214B-6FA2-408D-9E26-49699F4EEA0CQ35530143-975B239A-086E-44CD-BC71-0556C7E2A6BCQ35546665-50EA6ABA-9AC8-4140-B0CD-728216922639Q35550129-E5C50D7A-76C1-4A93-84DA-EDE959979873Q35592114-7B1F65F1-5BCF-4CE9-B0AC-54960CD7D11FQ35643712-A4BA6A0A-086E-4AE2-AC2A-3CD9AE169F58Q35755602-B38D49EC-8E02-42BD-BCED-A72357E7F68CQ35808069-1368ECAF-4381-4C51-AC77-1F58F83449A8Q35859205-FAD93C93-29AC-48D6-8A17-ADF1ABF22848Q36059002-8EE7FEF0-0C87-4B5C-B605-8295AB882F9AQ36095375-BA6F2EC3-EAD1-4996-B1F7-FB2D9C1ED5ABQ36309425-D7CC4D3F-04CA-4268-A212-9DC3BA809A12Q36310262-924D700B-EE57-4355-A26D-F6D3BF33FE0FQ36442900-C9CD12DC-D1A4-4A3A-9114-2498E80026A1Q36844176-2D7D4F27-FC67-4B0A-9406-F93D2B28D492Q37013260-870E5D98-6DEB-47DF-A18E-B053719A5854Q37198085-4A9B509A-4C9A-4869-8293-CC7CDEC2C101Q37204596-33BC9627-09C6-4199-B764-09F7833827D2Q37233917-23251C8F-AEDB-41F6-BB4E-439101D4D892Q37412555-A37068D0-FB45-443A-B0ED-45143F7DFFB2Q37459656-570C1BB2-BFBB-4F2D-A370-82EE8D965C83
P2860
Inhibition of HSP90 molecular chaperones: moving into the clinic.
description
2013 nî lūn-bûn
@nan
2013 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Inhibition of HSP90 molecular chaperones: moving into the clinic.
@ast
Inhibition of HSP90 molecular chaperones: moving into the clinic.
@en
Inhibition of HSP90 molecular chaperones: moving into the clinic.
@nl
type
label
Inhibition of HSP90 molecular chaperones: moving into the clinic.
@ast
Inhibition of HSP90 molecular chaperones: moving into the clinic.
@en
Inhibition of HSP90 molecular chaperones: moving into the clinic.
@nl
prefLabel
Inhibition of HSP90 molecular chaperones: moving into the clinic.
@ast
Inhibition of HSP90 molecular chaperones: moving into the clinic.
@en
Inhibition of HSP90 molecular chaperones: moving into the clinic.
@nl
P1433
P1476
Inhibition of HSP90 molecular chaperones: moving into the clinic.
@en
P2093
Luis Paz-Ares
P304
P356
10.1016/S1470-2045(13)70169-4
P577
2013-08-01T00:00:00Z